A combination of interleukin-2 and 60 nm cationic supramolecular biovectors for the treatment of established tumours by subcutaneous or intranasal administration

European Journal of Cancer

Volumn 37, Issue 8, 2001, Pages 1053-1060

  El mir, S ^a   Casanova, A ^b   Betbeder, D ^b   Triebel, F ^c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b Biovector Therapeutics   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Cytotoxicity; Formulation; Interleukin 2; Nanoparticle; Tumour immunity; Tumour model

Indexed keywords

DRUG CARRIER; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADENOCARCINOMA; ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INTRANASAL; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG CARRIERS; FEMALE; INTERLEUKIN-2; LIPIDS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; POLYSACCHARIDES;

EID: 0035035929     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00084-3     Document Type: Article

References (27)

1. Rational immunotherapy with interleukin 2
2. New approaches to the immunotherapy of cancer using interleukin-2
3. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors
4. Cancer vaccines
5. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
6. T-cell help cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
7. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
8. CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism
9. CD8+ T cells become nonresponsive (anergic) following activation in the presence of costimulation
10. Stabilization and enhancement of interleukin-2 in vitro bioactivity by new carriers: Supramolecular biovectors
11. Characterisation and phase behaviour of phospholipid bilayers adsorbed on spherical polysaccharide nanoparticles
12. Combination of human cytomegalovirus recombinant immediate-early protein (IE1) with 80 nm cationic biovectors: Protection from proteolysis and potentiation of presentation to CD4+ T-cell clones in vitro
13. LAG-3 induces tumor regression and antitumor immune responses in vivo
14. Functional consequences of IL-2 receptor expression on resting human lymphocytes: Identification of a novel NK cell subset with high affinity receptors
15. Inducing autoimmune disease to treat cancer
16. Low-dose IL-2 treatment: Activation of discrete T- and NK-cell sub-populations in vivo
17. Clonal T cell expansion induced by interleukin-2 therapy in blood and tumors
18. Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy
19. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4(+) T lymphocytes
20. Induction of secretory IgA response in the murine female urogenital tract by immunisation of the lungs with liposome-supplemented viral sub-unit antigen
21. Overview of interleukin inhalation therapy
22. Increased local antitumor effects of interleukin-2 liposomes in mice with MCA-106 sarcoma pulmonary metastases
23. Depot characteristics and biodistribution of interleukin-2 liposomes: Importance of route of administration
24. Immunotherapy of a mouse mammary carcinoma by sustained peritumor release of IL-2
25. Paracrine cytokine adjuvants in cancer immunotherapy
26. Cytokine depot formulations as adjuvants for tumor vaccines. I. Liposome-encapsulated IL-2 as a depot formulation
27. Liposomal formulation of a self lymphoma antigen induces potent protective antitumor immunity